Cyclerion Therapeutics, Inc. (CYCN): Price and Financial Metrics
CYCN Stock Summary
- Cyclerion Therapeutics Inc's stock had its IPO on March 18, 2019, making it an older stock than just 4.22% of US equities in our set.
- CYCN's price/sales ratio is 42.27; that's higher than the P/S ratio of 93.65% of US stocks.
- Revenue growth over the past 12 months for Cyclerion Therapeutics Inc comes in at -49.06%, a number that bests only 6.3% of the US stocks we're tracking.
- Stocks that are quantitatively similar to CYCN, based on their financial statements, market capitalization, and price volatility, are BLUE, MRKR, EVGN, TBPH, and APTX.
- CYCN's SEC filings can be seen here. And to visit Cyclerion Therapeutics Inc's official web site, go to www.cyclerion.com.
CYCN Stock Price Chart Interactive Chart >
CYCN Price/Volume Stats
| Current price | $2.82 | 52-week high | $8.96 |
| Prev. close | $2.85 | 52-week low | $2.18 |
| Day low | $2.75 | Volume | 121,352 |
| Day high | $2.96 | Avg. volume | 661,636 |
| 50-day MA | $3.82 | Dividend yield | N/A |
| 200-day MA | $4.29 | Market Cap | 96.04M |
Cyclerion Therapeutics, Inc. (CYCN) Company Bio
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest CYCN News From Around the Web
Below are the latest news stories about Cyclerion Therapeutics Inc that investors may wish to consider to help them evaluate CYCN as an investment opportunity.
TransMedics Appoints Stephanie Lovell to Board of DirectorsTransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Stephanie Lovell to its Board of Directors and as a member of the Nominating and Corporate Governance Committee, effective March 22, 2021. |
Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect ConferenceCAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overview at upcoming investor conferences: * 39th Annual J.P. Morgan Healthcare Conference. A presentation and Q&A discussion will take place on Thursday, January 14, 2021 at 3:40 p.m. ET and a live webcast may be accessed within the Investors & Media section of the Cyclerion.com website. An archived replay will be available for approximately 90 days following the presentation. * H.C. Wainwright BioConnect Conference. An on-demand presentation will be available on Monday January 11, 2021 at 6:00 a... |
Andreas Busch Is The Chief Innovation Officer of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) And They Just Picked Up 96% More SharesInvestors who take an interest in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) should definitely note that the Chief... |
Cyclerion to Participate at Upcoming September 2020 Investor ConferencesCAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company management will be participating in several upcoming September 2020 investor conferences: * Citi’s 15th Annual BioPharma Virtual Conference on September 9th * H.C. Wainwright & Co 22nd Annual Global Investment Conference on September 16th at 9:30 a.m. ET * Cantor Virtual Global Healthcare Conference on September 16th and a virtual Fireside Chat on September 17th at 3:20 p.m. ET * Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 21st –23rd on September 21st at 10:50 a.m.... |
Cyclerion Announces Translational Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant ProgramCAMBRIDGE, Mass., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing treatments for serious and orphan diseases, today announced that it has been awarded a grant from the Alzheimer's Association’s Part the Cloud-Gates Partnership Grant Program. This award will support the Company’s upcoming Phase 2 trial of IW-6463 in Alzheimer’s Disease with vascular pathology (ADv). The award provides Cyclerion with $2 million of funding over the next 2 years. “We are very pleased to have won this highly competitive award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program. Human genetic evidence and preclinical data suggest that stimulation of soluble guanylate cyclase (sGC) with IW-6463 can... |
CYCN Price Returns
| 1-mo | -33.96% |
| 3-mo | -15.82% |
| 6-mo | -15.82% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -7.84% |
| 2020 | 12.50% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...